Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.30 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15093192 | 0.89 | SLCO1B1 (0.36) | CNR2EGLN2EGLN1L3MBTL1 | |
| SCHEMBL15099681 | 0.86 | MAPT (0.34) | ADORA3L3MBTL1 | |
| SCHEMBL15099749 | 0.84 | ALDH1A1 (0.38) | — | |
| SCHEMBL15099630 | 0.83 | EPAS1 (0.34) | CNR2EPAS1TRPV4 | |
| SCHEMBL1699692 | 0.82 | ADORA3 (0.42) | ADORA3L3MBTL1 | |
| SCHEMBL15099726 | 0.74 | PTPN11 (0.32) | ADORA3 | |
| SCHEMBL15093265 | 0.73 | SLCO1B1 (0.33) | EPAS1 | |
| SCHEMBL15093252 | 0.72 | CYP3A4 (0.40) | PTGS1PTGS2 | |
| SCHEMBL1699756 | 0.71 | ADORA3 (0.42) | ADORA3L3MBTL1 | |
| SCHEMBL15099680 | 0.69 | MAPT (0.31) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2013103738-A1 | NAPTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | NFATC1, ACIN1, NAAA | CNR2 1449/4885ADORA3 182/4885PDCD1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.